Improving treatment for acute myeloid leukemia with IDH mutations
Project 1: Increasing therapeutic efficacy in isocitrate dehydrongenase (IDH)–mutant acute myeloid leukemia (AML)
This study is looking to improve treatments for people with acute myeloid leukemia who have certain gene mutations, by figuring out why some don’t respond to current medications and testing new combination therapies that could work better for them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10862892 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of treatments for patients with acute myeloid leukemia (AML) who have specific mutations in the IDH1 and IDH2 genes. By analyzing patient samples and conducting preclinical studies, the team aims to identify why some patients do not respond to existing IDH inhibitors and to develop new combination therapies that could improve outcomes. The research includes clinical trials that will test these new approaches in genetically defined patient groups, providing a tailored treatment strategy based on individual genetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who have mutations in the IDH1 or IDH2 genes.
Not a fit: Patients without IDH1 or IDH2 mutations or those with other types of leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with IDH-mutant acute myeloid leukemia, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results with IDH inhibitors in treating relapsed/refractory IDH-mutant AML, indicating that this approach has potential for further success.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Levine, Ross L — Sloan-Kettering Inst Can Research
- Study coordinator: Levine, Ross L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.